SEARCH RESULTS FOR:

Nader Elm & Raffi Jabrayan

CEO AND CO-FOUNDER & VP, BUSINESS DEVELOPMENT AND COMMERCIAL SALES, EXYN TECHNOLOGIES
Exyn Technologies explains how its drones operate autonomously underground with no need for connectivity or even a pilot.

NanaAma Botchway

MANAGING PARTNER, N. DOWUONA & COMPANY
MACIG 2022
N. Dowuona & Company is a predominantly female-owned and led law firm in Ghana and describes regulatory conditions for mining.

Stephen G. Roman

PRESIDENT AND CEO, GLOBAL ATOMIC
MACIG 2022
Global Atomic explains progress at its Dasa uranium project in Niger.

Gulferaz Ali

VP AND MANAGING DIRECTOR, EASTMAN ASIA PACIFIC (APAC)
Eastman continues to find exciting opportunities for growth in APAC.

Ronald Stewart

PRESIDENT & CEO, HIGHLANDER SILVER CORP.
Peru Mining 2022 Pre-Release Edition 2
Highlander Silver is a mineral exploration company focused on the further exploration of the Alta Victoria silver-polymetallic project in central Peru.

Sergio Aburto

LATIN AMERICA NORTH DIRECTOR, ACADIAN PLANT HEALTH
Acadian Plant Health explains how its crop care products based on seaweed can benefit Mexico’s farmers.

Verónica Pérez

PRESIDENT – NORTH REGION OF LATIN AMERICA, THE DOW CHEMICAL COMPANY
The Dow Chemical Company speaks to GBR about its Mexican opertaions.

Peter DeYoung

CEO, PIRAMAL PHARMA SOLUTIONS
Piramal Pharma Solutions comments on its continued global expansion.

Manni Kantipudi & Ramesh Subramanian

CHIEF EXECUTIVE OFFICER (CEO) AND CHIEF COMMERCIAL OFFICER (CCO), ARAGEN LIFE SCIENCES
Aragen Life Sciences explains how its expansion in both India and US can benefit drug discovery companies.

Laurent Nataf

CEO AND PRESIDENT, AZELIS ASIA PACIFIC
Singapore Chemicals 2021
Azelis comments on its rapid growth in Asia Pacific.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.

PARTNER EVENTS